© 2018 LP-DG® Science

Exit.st0{fill:none;stroke:#FFFFFF;stroke-width:2;stroke-linecap:round;stroke-linejoin:round;stroke-miterlimit:10;} .st1{fill:none;stroke:#00d9ff;stroke-width:1;enable-background:new;} .st2{fill:none;stroke:#FFFFFF;stroke-width:1;enable-background:new;}
Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial.
United European Gastroenterol J 2017, First Published October 8, 2017; 10 pages.

Evidence suggests a role of intestinal microbiota-host interactions in the pathophysiology and symptoms of irritable bowel syndrome (IBS).

The objective of this article is to assess the effects of Lactobacillus paracasei CNCM I-1572 on clinical and gut microbiota-related factors in IBS.

We conducted a multicenter, randomized, double-blind, cross-over, 18-week, placebo-controlled, pilot trial assessing the effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota composition, fecal short chain fatty acid (SCFA), immunoglobulin A, and cytokines in IBS. The intestinal microbial ecosystem was characterized by 16S rRNA gene profiling.

Forty IBS patients were enrolled from five Italian centers. Lactobacillus paracasei CNCM I-1572 did not significantly improve IBS symptoms, including primary efficacy variables worst abdominal pain/discomfort and IBS degree of relief. Interestingly, Lactobacillus paracasei CNCM I-1572 induced a significant reduction in genus Ruminococcus, dominated by taxa related to Ruminococcus bromii and Ruminococcus callidus, a significant increase in the SCFAs acetate and butyrate, and a significant reduction in the pro-inflammatory cytokine interleukin-15.

This pilot study shows that Lactobacillus paracasei CNCM I-1572 is able to modulate gut microbiota structure/function and reduce immune activation in IBS. As no statistically significant effect on IBS-symptoms was found, further studies are necessary to determine the role of this probiotic in IBS. The study was registered at ClinicalTrials.gov registry under identifier NCT02371499.

Cremon C, Guglielmetti S, Gargari G, Taverniti V, Castellazzi AM, Valsecchi C, Tagliacarne C, Fiore W, Bellini M, Bertani L, Gambaccini D, Cicala M, Germana B, Vecchi M, Pagano I, Barbaro MR, Bellacosa L, Stanghellini V, Barbara G

Cookie Policy

This website uses technical and profiling cookies collecting data in aggregate form. By closing this banner, scrolling this page or clicking any of its elements you consent to the use of cookies.

Healthcare professionals

Part of the information contained in this website is exclusively addressed to healthcare professionals. Please confirm that you are a healthcare professional. Are you a healthcare professional?

Yes, I am
No, I am not
Content to third part

This website contains links/references to third-party websites. By such links, SOFAR does not provide any guarantee nor gives its approval to their contents and quality. SOFAR does not have and does not accept any responsibility for the contents or the availability of such websites; SOFAR does not accept any liability for damage or injury resulting from the use of such contents, of whatever form. Users access such websites at their own risk. The information contained in this website is for information purposes only and not for diagnostic or therapeutic purposes. Thus, it does not substitute in any way medical and /or expert or other healthcare professionals or specialists ‘advice.

Duly noted